APA (7th ed.) Citation
Cai, P., Liu, J., Yu, C., Chen, Q., Huang, S., Zeng, L., . . . Huang, A. (2026). Cost-Effectiveness of olaparib plus bevacizumab versus bevacizumab monotherapy as first-line maintenance for patients with advanced ovarian cancer: A analysis from a Chinese healthcare perspective. DARU: Journal of Pharmaceutical Sciences, 34(2), 1-14.
Chicago Style (17th ed.) Citation
Cai, Pengxiang, Jin Liu, Caifen Yu, Qing Chen, Shan Huang, Lingjun Zeng, Yong Sun, and Aiwen Huang. "Cost-Effectiveness of Olaparib Plus Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance for Patients with Advanced Ovarian Cancer: A Analysis from a Chinese Healthcare Perspective." DARU: Journal of Pharmaceutical Sciences 34, no. 2 (2026): 1-14.
MLA (9th ed.) Citation
Cai, Pengxiang, et al. "Cost-Effectiveness of Olaparib Plus Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance for Patients with Advanced Ovarian Cancer: A Analysis from a Chinese Healthcare Perspective." DARU: Journal of Pharmaceutical Sciences, vol. 34, no. 2, 2026, pp. 1-14.
Warning: These citations may not always be 100% accurate.